Targeting elements of the PI3K/AKT axis such as G3BP1, PI3Kβ, or mutant PIK3CA can restore antitumor immunity and improve responsiveness to immune checkpoint inhibitors, offering promising strategies for treating cancers. This evidence concerns the gene PIK3CB and cancer.